Sequential single agents as first-line chemotherapy for ovarian cancer: A strategy derived from the results of GOG-132

International Journal of Gynecological Cancer

Volumn 13, Issue SUPPL. 2, 2003, Pages 156-162

  Muggia, Franco M ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Carboplatin; Chemotherapy; Cisplatin; Combination; Sequential

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; MATHEMATICAL MODEL; OVARY CANCER; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 1242297594     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2003.13351.x     Document Type: Conference Paper

References (34)

1. Levin L, Hryniuk WN. Dose-intensity analysis of chemotherapy regimens in ovarian cancer. J Clin Oncol 1987;5:756-67.
2. McGuire WP, Hoskins WJ, Brady MF et al. An assessment of dose-intense therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 1995;13:1589-99.
3. Kaye SB, Paul J, Cassidy J et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 1996;14:1213-9.
4. Gore P, Mainwaring P, A'hem R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J Clin Oncol 1998;16:2426-34.
5. Jodrell DI, Egorin MJ, Canetta RM et al. Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
6. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
7. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000;92:699-708.
8. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2000;18:105-15.
9. The ICON Collaborators. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trials. Lancet 2002;360:505-15.
10. Muggia FM. Classic Papers and Current Comments: Highlights of Gynecologic Cancer Research, Vol. 7. Ed. Canellos GP, Guest Ed. Cannistra SA. Baltimore: Lippincott Williams & Wilkins, 2002, 91.
11. Sandercock J, Parmar MKB, Torri V. First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78:1471-8.
12. Sandercock J, Parmar MKB, Torri V, Qian W. First-line chemotherapy for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815-24.
13. Thigpen JT, Lagasse L, Homesley H et al. cis-Platinum in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 1983;6:431-5.
14. Bruckner HW, Wallach R, Cohen CJ et al. High-dose platinum for the treatment of refractory ovarian cancer. Gynecol Oncol 1981;12:64-7.
15. Dembo A. Controversy over combination chemotherapy in advanced ovarian cancer: What we learn from reports of matured data. J Clin Oncol 1986;4:1573-5.
16. Edmondson JH, Fleming TR, Decker DG et al. Different chemotherapeutic sensitivities and host factors affecting prognosis in advanced ovarian carcinoma versus minimal residual disease. Cancer Treat Rep 1979;63:241-7.
17. Neijt JP, ten Bokkel Huinink W, van der Burg ME et al. Randomized trial comparing two combination chemotherapy regimens (hexa-CAF vs CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600.
18. Neijt JP, ten Bokkel Huinink W, van der Burg ME et al. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
19. Omura G, Blessing JA, Ehrlich CE et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncol Group study. Cancer 1986;57:1725-30.
20. Neijt JP. Combination chemotherapy in the treatment of advanced ovarian carcinoma. Doctoral Thesis. Utrecht University Hospital, Utrecht, The Netherlands, ICG Printing, Dordrecht, 1983.
21. Rozencweig M, Martin A, Beltangady M et al. Randomized trials of carboplatin versus cisplatin in advanced ovarian cancer. In: Carboplatin (JM-8). Current Perspectives and Future Directions. Eds Bunn PA, Canetta R Jr, Ozols RF, Rozencweig M. Philadelphia: W. B. Saunders Co, 1990, 175-86.
22. Gruppo Interregionale Cooperativo Oncologico Ginecologico. Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatininadvanced ovarian cancer. Lancet 1987;2:353-9.
23. Bolis G, Favalli G, Danese S et al. Weekly cisplatin given for 2 months, versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol 1997;15:1938-44.
24. The ICON Collaborators. ICON2: randomized trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet 1998;352:1571-6.
25. Hawes D, Liu PY, Muggia FM et al. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: A Southwest Oncology Group Ancillary study. Gynecol Oncol 2002;87:17-23.
26. Hudis C, Seidman A, Baselga J et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for respectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93-100.
27. Van der Zee AG, Hollema H, Suurmeijer AJ et al. Value of P-glycoprotein, glutathione-S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995;13:70-8.
28. Levesque MA, Katsaros D, Yu H et al. Mutant p53 overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
29. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
30. Klemi P, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H. p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995;76:1201-8.
31. Diebold J, Baretton G, Felchner M et al. Bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am J Clin Pathol 1995;105:341-5.
32. Anttila MA, Ji H, Juhola MT, Saarikoski SV, Syrjanen KJ. The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer. Int J Gynecol Pathol 1999;18:42-51.
33. Baekelandt M, Kristensen GB, Nesland JM, Trope CG, Holm R. Clinical significance of apoptosis-related factors p53, mdm2, and bcl-2 in advanced ovarian cancer. J Clin Oncol 1999;17:2061-8.
34. Buyse M, Burzykowki T, Parmar M et al. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. J Clin Oncol 2003;21:1682-7.